New Research Links Cannabis to Sustained Opioid Reductions and Arthritis Relief — the Policy Still Hasn’t Caught Up

Two peer-reviewed studies released this week add to a growing body of evidence that cannabis can meaningfully reduce opioid consumption and relieve pain in arthritis patients — findings that researchers say have direct implications for federal prescribing guidelines, DEA scheduling decisions, and the ongoing opioid crisis response. Yet with cannabis still classified as a Schedule I controlled substance at the federal level and rescheduling proceedings crawling through administrative review, the practical policy distance between what the science shows and what Washington allows remains vast.

The Opioid Study

The first study, flagged by the National Organization for the Reform of Marijuana Laws, examined chronic pain patients who incorporated cannabis therapy into their treatment regimen. The results were striking: patients showed sustained, not just temporary, reductions in opioid use over the course of the study period. Researchers concluded that “medical cannabis may be a useful adjunct therapy for reducing opioid use, relieving chronic pain, and improving health-related quality of life.”

The word sustained matters here. Critics of earlier cannabis-and-opioids research had long argued that any reductions in opioid consumption were short-lived or anecdotal, often reverting once the novelty wore off or once access barriers shifted. This study’s emphasis on durability pushes back against that line of criticism and lends the findings more weight in a clinical-policy context.

For advocates pressing the DEA and FDA to act on rescheduling, the data is another round of ammunition in a fight that has been grinding on for years. The Biden administration formally proposed moving cannabis from Schedule I to Schedule III in 2024 — a seismic shift in regulatory posture — but the rulemaking process has stretched well past initial timelines, with no final rule published as of this writing. The Trump administration’s DEA has offered few signals about how aggressively it intends to advance, slow-walk, or shelve that proposal.

Opioid policy is one place where those competing dynamics get particularly complicated. On one hand, any administration has political incentives to address the opioid crisis; fentanyl deaths have shaped electoral politics across the Rust Belt and rural America for a decade. On the other hand, acknowledging that cannabis is an effective opioid substitute requires implicitly validating the case for expanded access — a position that puts the current DEA in an awkward spot philosophically and politically.

The Arthritis Survey

The second study comes at the same problem from a different angle. A new survey found that nearly one in six arthritis patients — roughly 17 percent — report using cannabis to manage joint pain. Researchers recommended that orthopedic surgeons “proactively address cannabis use and perceptions as part of routine arthritis care.”

That’s not a small slice. Arthritis affects more than 54 million adults in the United States, making it the most common cause of disability in the country. If 17 percent of those patients are turning to cannabis, that represents roughly nine million Americans navigating a patchwork of state laws, inconsistent dispensary access, gaps in physician training, and total federal prohibition — all for something their orthopedic surgeon might not even be asking them about.

The survey’s recommendation that surgeons proactively open the conversation is notable in itself. Until relatively recently, many physicians declined to discuss cannabis at all — partly out of concern about their DEA prescriber registration, partly from a lack of clinical training, and partly because patients in prohibition states had little legal recourse regardless. That posture has been shifting as state-legal markets have matured, but the absence of federal approval still creates genuine obstacles: no FDA-approved cannabis products for arthritis, no standardized dosing guidance, no insurance reimbursement.

The Policy Gap

Taken together, the two studies land at a moment when the policy architecture governing medical cannabis is at genuine inflection point — or would be, if it were moving faster.

The Schedule III proposal, if finalized, would not legalize cannabis. It would not open the door to FDA-approved cannabis medicines overnight, nor would it resolve the banking exclusions that force cannabis businesses to operate in cash. But it would remove cannabis from the same tier as heroin and LSD, allow legitimate medical research to scale up, and potentially enable pharmaceutical-grade development of cannabis-based treatments for exactly the conditions these studies address.

That research pipeline is what federal officials point to when asked why the process has to be so slow. The FDA has maintained that proper clinical trials take time, that the evidence base — though growing — still contains significant gaps in dosing, formulation, and long-term safety. That is a defensible scientific position. It is also, advocates argue, a position enabled by the very scheduling status that made rigorous cannabis research nearly impossible for decades.

Louisiana took its own path this week, with the state legislature passing a bill that significantly increases marijuana penalties — including for violations in school zones. The bill’s sponsor said it would “ensure that violations in school zones result in real, enforceable consequences.” Louisiana’s approach is a reminder that the state-level policy landscape is not uniformly trending toward liberalization. For every state expanding access, there are others tightening enforcement, creating a jagged national map that makes the absence of a coherent federal framework feel increasingly untenable.

What Comes Next

For the DEA and FDA, the pressure to act on the rescheduling proposal is not going away. Studies like the ones released this week keep adding to the scientific case, even as political headwinds from conservative state legislatures and a skeptical federal law enforcement apparatus push in the other direction. The longer the rulemaking drags, the wider the credibility gap grows between an agency saying it weighs the evidence and an evidence base that keeps moving in one direction.

For patients — the nine million arthritis sufferers asking their doctors about cannabis, the chronic pain patients quietly substituting it for opioids — the wait has very concrete costs. Federal inaction doesn’t hold the status quo. It just means that people make decisions without medical guidance, without product standards, and without any safety net if something goes wrong.

The research will keep accumulating. The policy will catch up when it catches up.

Ethan Vale covers federal cannabis policy, DEA and FDA regulatory affairs, and Congress for CannabisInquirer.com.